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Introduction
There is a growing problem of antimicrobial resistance
among the pathogens isolated from hematology patients and
hematopoietic stem cell transplant (HSCT) recipients in many
centers, and this increasingly influences the choice of empiri-
cal therapy.1 Resistance also affects the choice of ‘targeted’
therapy once a pathogen has been isolated, identified and
subjected to susceptibility testing.  In some cases, treatment
options are very limited, and the emergence and proliferation
of multiresistant Gram-negative organisms – both
Enterobacteriaceae and non-fermenters – is forcing the
renewed use of old antibiotics, notably colistin/polymyxin B
and fosfomycin2-6 and of tigecycline. Similarly, the emergence
of Gram-positive pathogens resistant to β-lactams and gly-
copeptides is leading to the use of linezolid, daptomycin and
tigecycline in hematology patients. 
These agents have not been extensively trialed in hematol-
ogy patients; rather, their use is predicated on the lack of
alternatives. Additional concern is that onco-hematological
patients, and especially allogeneic HSCT recipients receive a
lot of drugs (e.g., cyclosporine, mycophenolate mofetil, tria-
zoles, antivirals) and they are likely more prone to drug-drug
interactions than other populations. We should therefore
reinforce the caution about the use of these antibiotics. For
this reason, the European Conference on Infections in
Leukemia (ECIL) group decided to review the published liter-
ature on the use of these non-conventional antibacterial
agents for use against resistant Gram-negative and -positive
pathogens in leukemic patients and HSCT recipients. The
resulting draft guidelines, presented here, were discussed by
the Expert Group at the ECIL-4 meeting in September 2011
and are based on published studies and expert opinion.
Updated slide sets from ECIL-4 covering these aspects are
available via the websites of the four organizations involved
in ECIL (European Group for Blood and Marrow
Transplantation, European Organization for Research and
Treatment of Cancer, Immunocompromised Host Society,
ECIL and European Leukaemia Net).7,8
Methods
The methodology of the ECIL conferences was described previous-
ly;9 the quality of evidence and strength of recommendations were
graded according to the criteria of the Infectious Disease Society of
America (IDSA)10 (Table 1). A group leader (MA) was proposed by the
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The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell
transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These
include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these
agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4th
European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations.
Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against
the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assess-
ment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be prefer-
ably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecy-
cline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future
should lead us to limit the use of these drugs to situations where no alternative exists. 
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organizing committee and experts were solicited to form the
working group. The group reviewed the published English-lan-
guage literature and prepared proposals on treatment options for
infections due to resistant bacteria. Papers for review were sought
using PubMed with the terms “linezolid”, “daptomycin”, “quin-
upristin/ dalfopristin”, “colistin or polymyxin”, “tigecycline”, “fos-
fomycin”, “telavancin”, “ceftaroline” AND “stem cell transplanta-
tion or bone marrow transplant or leukemia or hematological
malignancy or cancer”. References cited in the articles identified
were also considered. 
In respect of ‘Duration of therapy’, the main search terms used
were “antibiotic therapy”; “stem cell transplantation or bone mar-
row transplantation or hematological malignancy or cancer”;
“febrile neutropenia” and “duration therapy”, “discontinuation
antibiotics” and “microbiologically documented infection”.
Definitions of resistance
A bacterial isolate was considered non-susceptible if it was cat-
egorized resistant, intermediate or non-susceptible when using
clinical breakpoints of the European Committee on Antimicrobial
Susceptibility Testing (EUCAST), Clinical and Laboratory
Standards Institute (CLSI) or the US Food and Drug
Administration (FDA). Definitions of ‘MDR’ vary among authors
and usually presume resistance to at least two antibiotics used in
empiric therapy (3rd4th -generation cephalosporins, carbapenems or
piperacillin/tazobactam) or resistance to at least three of the fol-
lowing antibiotic classes: antipseudomonal penicillins,
cephalosporins, carbapenems, aminoglycosides and fluoro-
quinolones.11-15 According to the recent definition of the European
Centre for Disease Prevention and Control (ECDC) and the
Centers for Disease Control and Prevention (CDC), the isolate is
considered MDR if it is non-susceptible to at least one agent in ≥3
therapeutically relevant antimicrobial categories.16
Results of the literature review
Resistant Gram-negative rods 
Acquired resistance, now often encompassing carbapen-
ems as well as other drug classes, is a growing problem in
Enterobacteriaceae, Pseudomonas aeruginosa and
Acinetobacter baumannii, whereas Stenotrophomonas mal-
tophilia is inherently resistant to most antibiotics except
co-trimoxazole (trimetoprim-sulfamethoxazole; TMP-
SMX) and ticarcillin-clavulanate. The erosion of carbapen-
em activity against Enterobacteriaceae and A. baumannii
largely reflects the spread of carbapenem-degrading
enzymes, dubbed carbapenemases; these enzymes also
occur in P. aeruginosa, although multi-resistance in this
species, including to carbapenems, more often involves
mutational reductions in permeability and up-regulation
of efflux.17
Agents that retain some in vitro activity against most car-
bapenem-resistant Enterobacteriaceae isolates include
tigecycline, colistin/polymyxin B, fosfomycin and – more
variably – aminoglycosides. Interestingly, some carbapen-
emase-producing Enterobacteriaceae retain a degree of in
vitro susceptibility to carbapenems and, if carbapenems are
combined with other agents, they may still provide thera-
peutic benefit in these cases.18 In general, however, clinical
data on the treatment of carbapenem-resistant
Enterobacteriaceae infections are very limited and consist
mainly of small case-series and brief reports.18-25 The
prevalence of resistance in P. aeruginosa from HSCT
patients varies across Europe, increasing as one moves
south and eastward (ref. “Current etiology and resistance in
bacterial bloodstream infections in hematology and oncology
patients – literature review and ECIL-4 Surveillance Study.”  M.
Mikulska, C. Viscoli, C. Orasch, DM. Livermore, D. Averbuch,
C. Cordonnier, M. Akova. Submitted for publication). In some
centers, 25%-71% of P. aeruginosa isolates are MDR,11,14,15,26-
30 leaving colistin/polymyxin B and (maybe) fosfomycin as
the only treatment options. 
Carbapenem-resistant A. baumannii may remain suscep-
tible to sulbactam,31 a β−lactamase inhibitor that also has
clinically relevant intrinsic antimicrobial activity against
the organism. 
Other antibiotics that show in vitro activity against some
A. baumannii are colistin/polymyxin B and tigecycline.31
However, A. baumannii can develop resistance to tigecy-
cline by mutation, with the trait sometimes selected in
therapy;32-34 moreover some regionally prevalent MDR
strains are non-susceptible to tigecycline.35
In the case of S. maltophilia, TMP-SMX is considered the
treatment of choice, but resistance may arise and the sul-
fonamide component is poorly tolerated by some
patients.36-39 Alternative agents against S. maltophilia pro-
posed by some authors include the β-lactams, ticarcillin-
clavulanate and ceftazidime; fluoroquinolones, with mox-
ifloxacin reportedly active in vitro against some
ciprofloxacin-resistant isolates from hematological
patients;40 minocycline and chloramphenicol. Published
cases series are small with variable success and drugs often
in combination.37-39 The combination of TMP-SMX with
either ticarcillin/clavulanate or with a third-generation
cephalosporin (mainly ceftazidime) should be considered
ECIL-4 guidelines: multiresistant pathogens 
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Table 1. Infectious Diseases Society of America grading system for ranking recommendations.10
Category, grade Definition
Strength of recommendation
A Good evidence to support a recommendation for or against use
B Moderate evidence to support a recommendation for or against use
C Poor evidence to support a recommendation
Quality of evidence
I  Evidence from ≥ 1 properly- randomized, controlled trial
II Evidence from ≥1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies 
(preferably from >1 center); from multiple time-series; or from dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert
committees
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in neutropenic or severely ill patients.37,41,42 Review is fur-
ther complicated because in vitro susceptibility testing for
S. maltophilia is problematic, with results contingent on the
medium (β-lactams) and temperature (aminoglycosides)
used; the correlation with outcome is questionable.39
Treatment options against infections due to MDR
Gram-negative rods in leukemic and HSCT patients are
summarized in Table 2.
Tigecycline
Tigecycline has a broad-spectrum of in vitro activity
against MDR Gram-positive and Gram-negative bacteria,
excluding P. aeruginosa, Proteus spp., Providencia spp. and
Morganella spp.22,38,54,55 However, evidence of increased
mortality, compared to other antibiotic therapies, especial-
ly in ventilator-associated pneumonia48 leads to caution in
its use. Moreover, a serious drawback, at least for
monotherapy in bacteremia, is the low serum level
obtained.33 Superinfections with pathogens inherently
resistant to tigecycline (P. aeruginosa, Proteus spp.,
Providencia spp. and Morganella spp.) are another con-
cern.32,56 
Nevertheless, tigecycline was used at standard dosage,
in combination with an anti-pseudomonal drug (β-lac-
tams, quinolones, aminoglycosides) in 110 adult cancer
patients (58% with hematological malignancies and 24%
post-HSCT) as salvage therapy, for the treatment of refrac-
tory pneumonia (60%), bacteremia (17%) or other infec-
tions, which were microbiologically documented in 45%
of the patients.57 Not all isolates were susceptible, or were
tested to the antibiotics administered, concurrently with
the tigecycline. Clinical response was achieved in 56% of
transplant recipients, being higher in non-pseudomonas
than pseudomonas infections (80% vs. 50%, P=0.06).
Patients with pneumonia had lower response and higher
mortality rates than those with bacteremia (51% vs. 79%,
44% vs. 16% respectively, both P<0.05).57 In another
study, tigecycline was used at standard dosages for the
treatment of serious hospital-acquired infections caused
by MDR bacteria, including 50 patients (24%) with hema-
tological malignancies. Alone or combined with other
antibiotics, it showed efficacy in 16/23 (70%) of bac-
teremia cases and in 7/12 (58%) in whom it was used for
empirical treatment of febrile neutropenia.58 Higher-
dosage tigecycline regimens potentially may be advanta-
geous in severe infections. A recent randomized study in
patients with hospital-acquired pneumonia showed that
clinical cure with tigecycline 100 mg twice daily after a
loading dose of 200 mg (17/20, 85.0%) was numerically
higher than with tigecycline 75 mg twice daily after a
loading dose of 150 mg (16/23, 69.6%) and
imipenem/cilastatin (18/24, 75.0%).59 Tigecycline may also
D. Averbuch et al.
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Table 2. Main characteristics of the new or revisited antibacterial drugs for treatment of infections due to MDR Gram-negative bacteria.
Colistin/polymyxin B Tigecycline Fosfomycin 
(4, 6, 43-47) (4, 33, 48, 49) (50-53)
Class Polymyxin  Tetracyclines Phosphonic acid derivative
Mechanism of action, Disrupts bacterial membranes, Protein synthesis inhibition, Inhibits peptidoglycan synthesis, 
hydro/lipophilic Hydrophilic Lipophilic Hydrophilic
Bactericidal/-static; concentration/ Bactericidal, Bacteriostatic, Bactericidal,
time dependent activity Concentration dependent Time dependent Variable concentration-dependent
or time-dependent 
Spectrum Enterobacteriaceae, Enterobacteriaceae, Enterobacteriaceae (esp. E. coli), 
P. aeruginosa, A. baumannii, A. baumannii, S. maltophilia Some P.  aeruginosa,
S. maltophilia. Not P. aeruginosa, Proteus, Not A. baumannii
Not Proteus, Serratia, Providencia spp. Morganella and Providencia spp
Half life 5.9 ± 2.6 hours (following 37±12 h 5.7±2.8 h
administration of 2 million 
international units of colistin )
Route of elimination Methanesulphonate renal Biliary/fecal and renal Renal and fecal 
Dose and route Wide dose range used (3–9x106 IU/day). 100 mg loading dose followed by Range 2 gram 3 times daily up to
Loading dose 9 million IU and 50 mg twice daily, i.v. 4 grams 4 times daily, i.v.
maintenance dose 4.5 million IU 
every 12 h preferred, i.v.
Main side effects Nephrotoxicity, neurotoxicity Nausea, vomiting and headache Gastrointestinal (rare) 
Warnings Increased mortality as compared to Low blood levels; No clinical experience in this 
other appropriate regimens in some Increased risk of death compared patient population;
retrospective studies; to other antibiotics used Readily selects resistance
Low colistin concentration after to treat severe infections
the first few doses in the routine 
dose regimen
European Medicines Agency (EMA) Serious infections caused by Complicated skin and soft tissue No EMA license; individual country
labeled indications Gram-negative bacteria, including those infections, complicated licenses include infections of lung,
of the lower respiratory tract and intra-abdominal infections urinary tract and bone, 
urinary tract where sensitivity testing with associated bacteremia 
suggests that they are caused 
by susceptible bacteria 
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benefit from combination. In a prospective multicenter
trial of empirical for febrile neutropenic cancer patients,
successful outcomes were reported in 126 of 164 (74%)
treated with piperacillin-tazobactam plus tigecycline com-
pared to 90 of 190 (47%) patients treated with piperacillin-
tazobactam alone (P<0.01), although there was no differ-
ence in mortality. The success rate of the combined regi-
men was better than the piperacillin-tazobactam alone
also in bacteremias (60% vs. 27%, P<0.01) and clinically
documented infections (84% vs. 47%, P <0.01).60 
Polymyxins
Colistin (polymyxin E) and polymyxin B, which were
largely abandoned as systemic treatments from the 1960s
and 70s, are now increasingly used as the last-resort treat-
ment options against infections caused by MDR Gram-
negative pathogens. Although several studies have pre-
sented case series with positive outcomes, treatment with
colistin was associated with increased mortality as com-
pared with other appropriate regimens in one retrospec-
tive study including a small number of onco-hematologi-
cal patients.46 In another retrospective study, summarizing
the efficacy of colistin in the treatment of infections due to
MDR Gram-negative bacteria, multivariate analysis
showed that presence of hematological disease, including
malignancy, was itself associated with a decreased proba-
bility of survival.3 Two retrospective analyses that includ-
ed patients with (mainly hematological) malignancies
who were treated with colistin for MDR P. aeruginosa
infections obtained differing results.5,61 In one study, 31-
colistin-treated patients (45% with bacteremia, 55% with
pneumonia) were compared to those (n= 64) treated with
a non-colistin (β-lactam or quinolone) regimen. The col-
istin regimen achieved a higher rate of clinical response in
multiple logistic regression analysis (P=0.026; odds ratio
2.9 (1.5, 7.6), whereas microbiological response (48% vs.
41%) and infection-related death rates (26% vs. 17%)
were similar.5 The other study compared 26 patients (84%
bacteremic) receiving colistin to 26 patients receiving anti-
pseudomonal β−lactams and found similar rates of resolu-
tion of infection (77% vs. 65%) and mortality (11% in
both groups).61 Nephrotoxicity, which was reported in up
to 50% of patients receiving colistin/polymyxin B in older
studies, is much less frequent in newer studies, with rates
ranging from 10–30%.44 In the two Pseudomonas studies
just cited, no significantly increased nephrotoxicity
occurred in patients treated with colistin, as compared
with other agents (including aminoglycosides), although
one patient treated with colistin suffered from seizures.5,61
Among another 38 colistin treatment courses in adults and
children with hematological malignancy or HSCT,
nephrotoxicity developed in only 11%.62
The use of a 9-million-unit loading dose and high daily
dosages (4.5 million units twice daily) of colistin47 may
help to overcome the problem of low blood levels that
may have been responsible for the suboptimal efficacy of
polymyxins in some studies, leading to increased mortali-
ty, as well as to the selection of resistant strain vari-
ants.3,45,47,63 A recently-published prospective observational
study in intensive care unit patients with severe infections
due to Gram-negative bacteria susceptible only to colistin
recorded clinical cures in 82% of cases when colistin was
administered as a 9-million-unit loading dose followed by
9 million units daily, given in two doses, as maintenance
therapy.64 Combination of colistin/polymyxin B with
other agents to which the bacteria show in vitro sensitivity
is strongly encouraged (e.g. with aminoglycosides and/or
tigecycline for the treatment of infections due to Klebsiella
pneumoniaewith KPC carbapenemases).22-24 Nephrotoxicity
following combination with aminoglycosides is of con-
cern, though, and renal function should be monitored;
moreover, most Enterobacteriaceae with NDM (rather
than KPC) carbapenemases are broadly resistant to amino-
glycosides.65
Fosfomycin
Fosfomycin is another old, but increasingly revisited,
antibiotic with broad-spectrum in vitro activity against
Gram-positive and -negative bacteria, excluding
Acinetobacter spp. It is used mainly as an oral treatment for
community-acquired urinary tract infection (UTI), but
intravenous formulations are available in some countries.
Several studies estimate 80-90% of Enterobacteriaceae
with extended-spectrum β−lactamases (ESBLs) and car-
bapenemases to be susceptible to fosfomycin,51,66 but other
studies report that only 50% of Klebsiella spp. and fewer
than 30% of MDR P. aeruginosa to be susceptible.2,6 There
are no universally accepted specific species-related suscep-
tibility breakpoints;2 EUCAST has no breakpoints for fos-
fomycin vs. P. aeruginosa, but notes anecdotal evidence that
it may be efficacious, in combination, against strains with
minimal inhibitory concentrations (MICs) <128 mg/L.67
Due to the possibility of resistance developing during ther-
apy, fosfomycin should be used in combination with other
agents, selected according to the susceptibility results.51,68
Data on the efficacy of intravenous fosfomycin are limited
to case reports and small case series51 and there is no pub-
lished experience of treating invasive infections in onco-
hematological and HSCT patients. A retrospective study
in HSCT patients showed, that in a multivariate analysis,
exposure to fosfomycin (route of administration not spec-
ified) was associated with a significantly decreased inci-
dence of veno-occlusive liver disease.69
Sulbactam
Although sulbactam is conventionally used as a β-lacta-
mase inhibitor, it also has inherent antibiotic activity against
Acinetobacter spp.31 The package insert of sulbactam says that
the maximum daily dose of sulbactam should not exceed 4
g. However, there are reports on dosages of sulbactam
(combined with β lactams) of at least 6 g IV in divided
dosages, assuming normal renal function.31,70 Furthermore,
doses of up to 9-12 g/day were administered for ventilator-
associated pneumonia with MDR Acinetobacter.71
Combination therapy in infections due to resistant
Gram-negative bacteria
Several meta-analyses of randomized controlled studies,
some of them done before the present era of increasing
resistance, concluded that there was similar all-cause mor-
tality in febrile neutropenic patients treated with a β-lac-
tam vs. the same β-lactam plus an aminoglycoside as
empirical or definitive therapy.72-74 However, owing to the
small numbers of cases of infection due to resistant bacte-
ria, a benefit of combination therapy could not be ruled
out for those patients who were critically ill or were
infected with P. aeruginosa or some other resistant
pathogen.72-74
Combination antibiotic therapy also may simply
improve the likelihood that at least one component agent
ECIL-4 guidelines: multiresistant pathogens 
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is active.75 A retrospective study reviewed patients with
hematological malignancies or post-HSCT, who were
infected by ESBL- or AmpC-producing Enterobacteriaceae
or resistant pseudomonas, most of whom were empirical-
ly treated with combination of a β-lactam and an amino-
glycoside. Mortality was lower among those patients
whose pathogen was sensitive in vitro to either the β-lac-
tam or the aminoglycoside, compared with those whose
pathogen was resistant to both (OR, 1.8; 95% CI, 1.3 to
2.5).76
Nevertheless, and in contrast, an early prospective ran-
domized trial in non-neutropenic patients, in the era prior
to the emergence of significant imipenem resistance,
showed that the combination of imipenem plus netilmicin
was no more efficacious than imipenem monotherapy for
the treatment of severe infections, but did have increased
nephrotoxicity, and did not prevent the emergence of
imipenem-resistant P. aeruginosa.77
Some in-vitro data suggest synergy in combining two
agents against carbapenemase-producing K. pneumoniae,
even when the pathogen is resistant to one of these
agents.78,79 Synergy was claimed for a combination of
polymyxin B and either rifampin or doxycycline, resulting
in at least a four-fold decrease in the MIC of polymyxin B
when both drugs were used at physiologically achievable
concentrations in one study.78 In another study a combina-
tion of fosfomycin with meropenem or colistin was
asserted to be synergistic, based on 100-fold more exten-
sive killing than with the more active single agent.79
Nevertheless there is a profound lack of clarity on when
and how the various different measures of synergy used in
vitro translate into clinical advantage; moreover there must
be a concern about publication bias: studies that detect
synergy are more likely to be reported and published than
those that fail to do so.
Carbapenem-containing regimens were associated with
significantly reduced mortality compared to non-car-
bapenem-containing regimens in a retrospective analysis
of 138 patients who received treatment for infections due
to carbapenemase-producing K. pneumoniae that showed
susceptibility to carbapenems in vitro. Carbapenems may
be a reasonable treatment option against carbapenemase-
producing K. pneumoniae provided that: (i) the carbapenem
MIC for the infecting organism is ≤4 mg/L; (ii) a high-dose
prolonged-infusion regimen is administered to drive the
pharmacokinetic/ pharmacodynamic profile to acceptable
exposures; and (iii) this class of agent is administered in
combination with another active compound.21 The caveat
is that many carbapenemase producers are more substan-
tially resistant, precluding such strategies.
An ertapenem-doripenem combination may be of
potential usefulness against KPC-producing K. pneumoniae
based on a study in an immunocompetent murine thigh
infection model based on the notion that the high affinity
of KPC for ertapenem would “trap” the enzyme thus
enhancing the activity of doripenem.80
Others have found that various combinations of
rifampin, β−lactams, aminoglycosides, quinolones, col-
istin/polymyxin B, fosfomycin or other agents are syner-
gistic in vitro, or in animal models, against MDR
Pseudomonas or Acinetobacter spp.2,31,81,82 Many authors argue
that rifampin should be considered for addition to other
active antibiotics in the treatment of uncontrolled infec-
tion due to MDR bacteria,31,55,78,83-85 though there is little evi-
dence of why rifampicin should improve outcome and no
randomized trials to show that it does improve these out-
comes.  Further obstacles include: (a) there is no relevant
in vitro breakpoint for susceptibility to rifampin against
Gram-negative bacteria; (b) toxic potential of rifampin; (c)
multitude of drug interactions between rifampin and other
agents, a main concern especially in onco-hematological
patients and allogeneic HSCT recipients who receive a lot
of other drugs concomitantly (such as cyclosporine,
mycophenolate mofetil, antifungals, antivirals).86 
Notably, a randomized, open-label recently published
clinical trial, which enrolled 210 patients with life-threat-
ening infections due A. baumannii that were susceptible
only to colistin showed that 30-day mortality was not
reduced by addition of rifampicin.86
Publication of further observational studies assessing
different monotherapies and combinations against MDR
Acinetobacter or carbapenem-resistant Gram-negative
bacteria is pending.87,88
Resistant Gram-positive pathogens 
Treatment options against infections due to resistant
Gram-positive bacteria in leukemic and HSCT patients are
summarized in Table 3.
Glycopeptide non-susceptible Gram-positive bacteria
include vancomycin-resistant enterococci (VRE) and van-
comycin-intermediate and hetero-resistant Staphylococcus
aureus (VISA and hVISA). There is also evidence that van-
comycin MICs at the high end of the normal range for
MRSA (2 mg/L) are associated with worse outcomes than
MIC of <1 mg/L.104 Infections with VRE are prevalent in
onco-hematological and HSCT patients in some coun-
tries105-110 but, until now, infections with VISA or hVISA
remain rare in this patient population.111-113
Agents showing activity against some glycopeptide
non-susceptible Gram-positive pathogens include linezol-
id, daptomycin, quinupristin/dalfopristin, tigecycline and
fosfomycin, as well as the new agents telavancin and cef-
taroline. The exact spectra of these agents vary and should
be considered before use. Linezolid and tigecycline are
almost universally active, whereas quinupristin/dalfo-
pristin for example, does not cover E. faecalis, telavancin is
inactive against VanA enterococci and ceftaroline lacks
activity against E. faecium and is variable against E. faecalis.
Linezolid is the only one of these antibiotics that has
been compared to vancomycin in a relevant prospective
double-blind, multicenter equivalence study. This was
performed in 605 febrile neutropenic cancer patients with
proven (24%) or suspected Gram-positive infections: 94%
had hematological malignancy. The study showed equiv-
alent efficacy between vancomycin and linezolid in
achieving clinical (87% vs. 86%) and microbiological (58%
vs. 50%) success. Mortality rates, too, were similar (5.6%
vs. 7.6%), though there were fewer drug-related adverse
events with linezolid (17.2% vs. 24%; P=0.04).114 Another
prospective, multicenter, open-label, non-comparative,
non-randomized study examined the performance of line-
zolid in 103 neutropenic cancer patients with serious
Gram-positive infections, mainly bacteremia.  Most
patients had VRE resistant to other therapies, or had a his-
tory of failure or intolerance to available agents. Linezolid
achieved 79% clinical and 86% microbiological cure
rates.115
Despite these positive findings, there is a concern about
the thrombocytopenia and/or neutropenia found in some
studies with linezolid. This side effect was seen in 2-11%
D. Averbuch et al.
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of patients,115,116 although two further studies suggested
that the incidence was similar to that with van-
comycin.114,117 Other uncommon but serious adverse
effects associated with linezolid include lactic acidosis,
serotonin syndrome, and peripheral and optic neu-
ropathies.118-120
Quinupristin/dalfopristin (QD) was compared to line-
zolid in a prospective randomized trial in 40 patients with
hematological malignancies (a third were post-HSCT,
20% neutropenic) with VRE infections, predominantly
bacteremia. Both regimens achieve comparable clinical
(43% vs. 58%) and microbiological (71% vs. 90%) cure
rates, with similar mortality (10% vs.16%).116 Comparable
results were achieved in treating staphylococcal line-asso-
ciated bacteremia with quinupristin/dalfopristin or van-
comycin in a prospective randomized comparative study
that included cancer patients.121 The response rate in van-
comycin-resistant E. faecium infections, mainly bac-
teremias, was 55%-68% in two studies that largely includ-
ed leukemia patients, including those with HSCT and neu-
tropenia,122,123 in one of these studies quinupristin/dalfo-
pristin was combined with minocycline.123 Arthralgia or
myalgia developed in 6-36% of patients.99,122
Quinupristin/dalfopristin should preferably be adminis-
tered via central venous catheter.99,122
Daptomycin treatment of probable or definite catheter-
related bacteremia caused by Gram-positive bacteria
resulted in a better overall response rate as compared with
matched historical controls treated with vancomycin -
68% vs. 32% (P=0.003);124 70% of these patients had
hematological malignancy and 13% were post-HSCT. In
another retrospective study, treatment with daptomycin
led to improvement in 90% of 72 febrile cancer patients
(82% with hematologic malignancies, 47% neutropenic)
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Table 3. Main characteristics of the new or revisited antibacterial drugs for treatment of resistant Gram-positive bacteria.
Linezolid Daptomycin Quinupristin/ Tigecycline Fosfomycin 
(89-91) (92-97) dalfopristin (6, 49, 48, 102) (50-53, 98, 103)
(98-101)
Class Oxazolidonone Lipopeptide Streptogramin Tetracycline Phosphonic acid derivative
Mechanism of action, Protein synthesis Plasma membrane Protein synthesis Protein synthesis Inhibits peptidoglycan
hydro/lipophilic inhibition, Lipophilic disruption, Hydrophilic inhibition, inhibition, synthesis, Hydrophilic
core with a lipophilic tail Lipophilic Lipophilic
Bactericidal/-static; Bacteriostatic, Bactericidal, Bacteriostatic Bacteriostatic, Bactericidal, 
concentration/time Time dependent Concentration against E. faecium Time dependent Variable concentration-
dependent activity dependent and bactericidal dependent or 
against staphylococci, time-dependent 
Time dependent
Spectrum MRSA, VISA, VRE, MRSA, some VISA, some MRSA, VISA, VRE MRSA, VISA, VRE, MRSA, some VRE (only 
β−lactam-resistant VRE, β−lactam-resistant (only E. faecium), β−lactam-resistant E. faecalis)
streptococci streptococci, β−lactam-resistant streptococci
streptococci
Half life 3.4–7.4 h 8 h Quinupristin- 0.85 h; 37±12 h 5.7±2.8 h
Dalfopristin- 0.7 h
Route of elimination Renal and fecal Renal (predominantly) Fecal (predominantly) Liver Renal (predominantly)
and fecal and renal and fecal
Dose and route 600 mg twice daily, i.v./po 4-6 mg/kg 7.5 mg/kg 3 times daily, 100 mg loading dose Range 2 grams 3 
once daily (routine dose); i.v. (preferably via followed by 50 mg times daily up to 4 grams
10-12 mg/kg once daily central venous catheter) twice daily, i.v. 4 times daily, i.v.
may be considered, i.v.
Main side effects Myelosuppression Constipation, nausea, Injection site reactions; Nausea, vomiting; Gastrointestinal, low rate
vomiting, diarrhea; Conjugated Headache
Rash; Increased creatine hyper-bilirubinemia
kinase
Warnings Myelosuppression Not indicated for Low blood levels; No clinical experience 
pneumonia; Staphylococci Increased risk in our patient population;
with reduced vancomycin of death compared Low threshold 
susceptibility may be less to other antibiotics of resistance
susceptible to daptomycin used to treat severe
infections
European Medicines Complicated skin and Complicated skin and Complicated skin and soft Complicated skin and No EMA license; individual
Agency (EMA) labeled soft-tissue infections, soft tissue infections; tissue infections; soft tissue infections, country licenses include
indications Community-acquired and Bacteremia due to nosocomial pneumonia complicated infections of lung, urinary
nosocomial pneumonia; Staphylococcus aureus, and VRE infections intra-abdominal tract and bone, with
including right-sided when there is infections associated bacteremia 
endocarditis documentation such 
that no other agent is suitable
VRE: vancomycin resistant Enterococcus, MRSA: methicillin resistant Staphylococcus aureus, VISA: vancomycin-intermediate Staphylococcus aureus.
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with infections, predominantly bacteremias, due to
Gram-positive organisms.125 None of the patients required
discontinuation of the daptomycin due to adverse
effects.125 The MIC of daptomycin should be checked for
staphylococci previously exposed or resistant to gly-
copeptides, as cross-resistance is possible, due to the
thickened cell wall trapping daptomycin.93,95,126 Use in
enterococcal bacteremia is off-label and MICs should be
carefully checked, as those for E. faecium are commonly
around 2-4 mg/L, well above the staphylococcal break-
point.95 In a small report, only four of nine febrile neu-
tropenic patients with vancomycin-resistant E. faecium
bacteremia had clinical and microbiological cure with
daptomycin, and only five survived for 30 days.127 In this
context the use of daptomycin at 10-12 mg/kg daily-well
above the currently licensed 4–6 mg/kg dose - may be jus-
tified, especially for high inoculum infections, but clinical
data are limited and side effects remain to be evaluated in
large-scale clinical trials.95,128,129
Tigecycline shows in vitro activity against glycopeptide-
non-susceptible Gram-positive bacteria; studies that con-
sidered its activity were outlined above in the section on
Gram-negative pathogens.57,58
Other new agents active against some resistant Gram-
positive bacteria include lipoglycopeptides (e.g., tela-
vancin) and anti-MRSA β-lactams (e.g. ceftaroline), whilst
fosfomycin – an old agent - is active against many MRSA
and VRE, especially E. faecalis, at least in vitro.103 As yet,
though, there is no published experience with these
agents in hematological and neutropenic patients. 
Duration of targeted therapy
There are several studies reporting that the duration of
treatment for microbiologically documented infections
(MDI) is at least 7 days.130-137 Others reported on 10-14
days of therapy.138,139 Some studies required some evidence
of bone marrow recovery.138-141 Repeated blood cultures
had to be sterile, and control of local infection, if any,
needed to be achieved. In a few of the studies patients
were afebrile for at least 24 hours138-142 while in the other
reports the patients were afebrile for at least 4–5
days.130,133,134,136,143
ECIL-4 recommendations
Based on in vitro susceptibility, the options for targeted
treatment of infections due to resistant Gram-negative and
Gram-positive bacteria are shown in Table 4. As most of
these options have not been assessed in large randomized,
prospective studies, at least in hematology populations,
their use should be approached with caution and should
be carefully discussed with the microbiologists or infec-
tious diseases specialist, taking in account also the
risk/benefit balance and safety profile of each drug on an
individual basis.
As shown in Table 4, colistin/polymyxin B are the pre-
ferred agents for treatment of infections due to β−lactam-
resistant Enterobacteriaceae, so long as the organism is
susceptible in vitro. A loading dose and high maintenance
dose may be required.
Tigecycline has wide in vitro activity, but should be used
with caution in bacteremia, as it achieves low blood levels.
Alternatives should be considered in patients with severe
infections, especially ventilator-associated pneumonia,
due to the higher mortality seen in the tigecycline arms of
comparative trials,48,144 Resistance can develop on treat-
ment.
Combination therapy, based on in vitro susceptibility
tests, should be considered when colistin/polymyxin B,
tigecycline, aminoglycosides and fosfomycin are used for
the treatment of infections due to resistant Gram-nega-
tives. Addition of rifampin can be considered.
The options for targeted treatment of infections due to
resistant Gram-positive bacteria are wider than against
Gram-negative bacteria. If linezolid is used, monitoring of
bone marrow recovery is important because of the possi-
bility of myelosuppression. Patients with suspected or
overt pneumonia should not be treated with daptomycin,
which is inactivated in lungs.
In general, the patient should be treated using narrower-
spectrum agents active against the pathogen identified, if
it is plausible and/or clinically significant, guided by in vitro
susceptibility tests, including MICs when available, and
based on knowledge on drugs with specific activities (e.g.
TMP-SMX for S. maltophilia) AI.
Penicillins and penicillin/β-lactamase inhibitors should
be preferred over cephalosporins and carbapenems if they
have comparable in vitro activity, spectrum of coverage and
drug concentration at site of infection BII. A more drastic
narrowing of the antibiotics could be envisaged if a fully-
susceptible organism is documented from blood cultures
of a stable patient under hospital observation, e.g. step
down to an amino- or ureido- penicillin (ampicillin or
piperacillin) when an a-haemolytic streptococcus is isolat-
ed BIII.
Duration of targeted therapy for microbiologically 
documented infections. 
Antibiotic treatment should be continued for at least 7
days, until the infection is microbiologically eradicated
and all clinical signs of infection are resolved, with the
patient afebrile for at least 4 days BIII. If the patient is still
neutropenic and antibiotic therapy is stopped, (s)he
should be kept hospitalized under close observation for at
least 24-48 hours. If fever recurs, antibiotics should be re-
started urgently after obtaining blood cultures and per-
forming other relevant evaluation based on clinical judg-
ment. 
Centers that give prophylactic antibacterial agents
should consider renewing this regimen upon discontinua-
tion of targeted antibiotic therapy, if the patient is still
neutropenic CIII.
Discussion
BSI develops in 13% to 60% of HSCT recipients14,26,108,145-147
and in 21-36% of neutropenic leukemia patients.131,136,146,148-151
Rates in other hematology patients are less well docu-
mented. 
It is of utmost importance to recognize infections due to
resistant bacteria and to target the therapy appropriately,
based on: (i) in vitro susceptibility, (ii) knowledge of the
best treatment option against the particular species and
resistance phenotypes, and (iii) a careful assessment of the
risk-benefit balance, according to the expected toxicity of
the drug(s). Narrower-spectrum agents should be used
whenever possible, so long as they have equivalent activ-
ity and efficacy. Pharmacokinetic and pharmacodynamic
D. Averbuch et al.
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data in individual situations should also be taken in
account.
Combinations of antibiotics are often required, as resist-
ance can develop on treatment (e.g., fosfomycin), or
because of suboptimal efficacy as monotherapy (e.g., tige-
cycline). Nevertheless the evidence that combinations
improve outcomes or prevent the emergence of resistance
is scanty at best, and the relationship of in vitro and in vivo
synergy is unclear. 
The paucity of new antibacterial drugs expected in the
near future should lead us to limit the use of the drugs dis-
cussed here to documented infection where there is no
other alternative. In this context, a strong collaboration is
needed between the hematologist, microbiologist, antimi-
crobial pharmacist and infectious disease specialist. The
best treatment option is uncertain in many cases, and
many combinations have not been formally assessed, pre-
cluding recommendations based on the principles of “evi-
dence-based medicine”. There is a great need to study and
monitor the efficacy of these non-conventional antibiotics
in the leukemic population.
Whilst current increases in bacterial resistance among
leukemic and HSCT patients restrict treatment choices
and force the use of the compounds discussed here, it
should never been forgotten that they are poorer therapies
than the compounds they replace, with clear evidence that
colistin and tigecycline are inferior to other antibiotics if
the pathogen is susceptible to them.46,48,144 If the underlying
problem is the spread of resistant clones of bacterial
among the patients in a unit, the best answer is the rein-
forcement of infection control, not the use of more exotic
and complex antimicrobial chemotherapy. Antimicrobial
stewardship, aiming to minimize unnecessary broad spec-
trum antibiotic use and its associated collateral damage
and resistance selection is likewise crucial in the present
era of growing resistance.
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Table 4. ECIL4 Recommendations: targeted treatment of infections
due to resistant Gram-negative and -positive bacteria (based on 
in vitro susceptibility).
Resistant bacteria Treatment options
Carbapenem-resistant        – Colistin/polymyxin B* BII
Enterobacteriaceae – Tigecycline* BIII
– Aminoglycosides* BIII
– Fosfomycin* CIII
Beta-lactam-resistant** – Colistin/polymyxin B*  AII
Pseudomonas aeruginosa – Fosfomycin* CIII
Beta-lactam-resistant** – Colistin/polymyxin B*  BIII
Acinetobacter spp. – Tigecycline* BIII
Stenotrophomonas maltophilia – Trimethoprim-sulfamethoxazole
(TMP-SMX)  AI – Fluoroquinolone (ciprofloxacin or
moxifloxacin) BII
– Ticarcillin-clavulanate BII
– In seriously-ill or neutropenic 
patients, combination therapy 
can be considered (e.g. TMP-SMX +
ceftazidime or ticarcillin-
clavulanate) CIII
Vancomycin-resistant – Linezolid AII
Enterococcus faecalis – Daptomycin  BII
– Tigecycline BIII
Vancomycin-resistant – Linezolid AII
Enterococcus faecium – Tigecycline BIII
– Quinupristin/dalfopristin BIII
Vancomycin-intermediate – Linezolid AII
Staphylococcus aureus – Tigecycline BIII
– Quinupristin/dalfopristin BIII
– Daptomycin  BII
*All these agents should be preferably used in combination with other in vitro active
agents. Addition of rifampin can be considered. **including carbapenems for both P. aerug-
inosa and Acinetobacter spp.; and ampicillin sulbactam for Acinetobacter spp.
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